Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. reported a significant increase in revenue for the first half of 2025, driven by strong sales of its key products, telitacicept and disitamab vedotin. The company achieved several milestones, including the approval of telitacicept for generalized myasthenia gravis in China and its designation as an Orphan Drug in Europe. Disitamab vedotin also received marketing approval in China for HER2-positive advanced breast cancer, marking a substantial advancement in their product pipeline. These developments are likely to enhance RemeGen’s market position and offer promising implications for stakeholders.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$59.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a pharmaceutical company based in China, focusing on the development and commercialization of treatments for autoimmune diseases and solid tumors. Their primary products include telitacicept for autoimmune diseases and disitamab vedotin for solid tumors.
Average Trading Volume: 11,836,738
Technical Sentiment Signal: Buy
Current Market Cap: HK$47.71B
For detailed information about 9995 stock, go to TipRanks’ Stock Analysis page.